Related Experiment Video
Updated: Oct 10, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Tumor Antigen-Based Nanovaccines for Cancer Immunotherapy: A Review
Jiaxuan Zhao1, Guangsheng Du1, Xun Sun1
1Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Abstract:
As an important means of tumor immunotherapy, tumor vaccines have achieved exciting results in the past few decades. However, there are still many obstacles that hinder tumor vaccines from achieving maximum efficacy, including lack of tumor antigens, low antigen immunogenicity and poor delivery efficiency. To overcome these challenges, researchers have developed and investigated various new types of tumor antigens with higher antigenic specificity and broader antigen spectrum, such as tumor-specific peptide antigens, tumor lysates, tumor cell membrane, tumor associated exosomes, etc. At the same time, different nanoparticulate delivery platforms have been developed to increase the immunogenicity of the tumor antigens, for example by increasing their targeting efficiency of antigen-presenting cells and lymph nodes, and by co-delivering antigens with adjuvants. In this review, we summarized different types of the tumor antigens that have been reported, and introduced several nanovaccine strategies for increasing the immunogenicity of tumor antigens. The review of recent progress in these fields may provide reference for the follow-up studies of tumor antigen-based cancer immunotherapy.
Insights
This review explores novel tumor antigens and nanovaccine strategies to enhance cancer immunotherapy efficacy. It addresses challenges like antigen scarcity and poor delivery for improved tumor vaccine performance.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Tumor vaccines are crucial for cancer immunotherapy, but face challenges like limited tumor antigens, low immunogenicity, and inefficient delivery.
- Overcoming these obstacles is key to maximizing the therapeutic potential of cancer vaccines.
Purpose of the Study:
- To review various tumor antigens and nanovaccine delivery strategies for enhancing cancer immunotherapy.
- To provide insights into recent advancements for future research in tumor antigen-based cancer immunotherapy.
Main Methods:
- Summarizing different types of tumor antigens (e.g., peptides, lysates, exosomes).
- Introducing nanovaccine platforms designed to boost antigen immunogenicity and delivery efficiency.
- Discussing strategies for targeting antigen-presenting cells and lymph nodes, and co-delivery with adjuvants.
Main Results:
- Identification of diverse tumor antigens with improved specificity and spectrum.
- Development of nanoparticulate delivery systems enhancing antigen targeting and immune cell interaction.
- Nanovaccines show promise in increasing antigen immunogenicity and delivery efficiency.
Conclusions:
- Novel tumor antigens and nanovaccine strategies offer promising solutions to current cancer immunotherapy limitations.
- Further research in this area can significantly advance the development of effective tumor vaccines for cancer treatment.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...